<DOC>
	<DOCNO>NCT01329913</DOCNO>
	<brief_summary>This 2 part study safety , pharmacokinetics pharmacodynamics MK-6325 HCV-infected participant . Part I study Genotype ( GT ) 1 HCV-infected participant randomize receive either MK-6325 placebo . If drug show safe efficacious Part I , Part II enroll GT 3 HCV-infected participant randomize receive either MK-6325 placebo .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics MK-6325 Hepatitis C Virus ( HCV ) Infections ( MK-6325-003 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Inclusion criterion : Body mass index ( BMI ) 18 ≤37 kg/m^2 . Stable health No clinically significant abnormality electrocardiogram ( ECG ) Clinical diagnosis chronic HCV infection ( G1 G3 ) least 6 month detectable HCV RNA peripheral blood . Exclusion criterion : Pregnancy intention become pregnant father child course study . History stroke , chronic seizure , major neurological disorder , uncontrolled clinically significant psychiatric disorder ( example , depression ) . Estimated creatinine clearance ≤70 mL/min . History clinically significant endocrine , gastrointestinal ( except HCV infection ) , cardiovascular , hematological , immunological , renal , respiratory , genitourinary abnormality diseases whose current condition consider clinically unstable . History neoplastic disease adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix ≥10 year prior prestudy ( screen ) visit evidence recurrence likelihood recurrence . Positive Hepatitis B surface antigen prestudy ( screen ) visit . History document HIV infection positive HIV serology prestudy ( screen ) visit . Regular consumption excessive amount alcohol , define great 2 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit [ 25 mL/1 ounce ] ) per day . Excessive consumption , define great 6 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , caffeinated beverage per day . Major surgery , donation loss 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior prestudy ( screen ) visit . History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food . Regular use ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 2 month . Exception : marijuana use permit discretion investigator provide participant refrain use study . Evidence history chronic hepatitis cause HCV include limited nonHCV viral hepatitis , nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis . Note : Participants history acute nonHCVrelated hepatitis , resolve &gt; 6 month study enrol . Previous treatment HCV protease inhibitor ≤3 month prior first dose study drug . Previous exposure interferonalpha and/or ribavirin within 3 month prior first dose MK6325 study . Clinical laboratory evidence advance decompensated liver disease ; evidence bridge fibrosis high grade fibrosis ( Metavir score ≥3 ) prior liver biopsy . Note : liver biopsy require entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>